NCT04351243: A reported trial by Kinevant Sciences GmbH
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04351243 |
|---|---|
| Title | A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 15, 2020 |
| Completion date | Dec. 1, 2020 |
| Required reporting date | Dec. 1, 2021, midnight |
| Actual reporting date | Nov. 26, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |